Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates

Y. Yamada, T. Ochiai, S. Boskovic, O. Nadazdin, T. Oura, D. Schoenfeld, K. Cappetta, R. N. Smith, R. B. Colvin, J. C. Madsen, D. H. Sachs, G. Benichou, A. B. Cosimi, T. Kawai

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We have previously reported successful induction of renal allograft tolerance via a mixed chimerism approach in nonhuman primates. In those studies, we found that costimulatory blockade with anti-CD154 mAb was an effective adjunctive therapy for induction of renal allograft tolerance. However, since anti-CD154 mAb is not clinically available, we have evaluated CTLA4Ig as an alternative agent for effecting costimulation blockade in this treatment protocol. Two CTLA4Igs, abatacept and belatacept, were substituted for anti-CD154 mAb in the conditioning regimen (low dose total body irradiation, thymic irradiation, anti-thymocyte globulin and a 1-month posttransplant course of cyclosporine [CyA]). Three recipients treated with the abatacept regimen failed to develop comparable lymphoid chimerism to that achieved with anti-CD154 mAb treatment and these recipients rejected their kidney allografts early. With the belatacept regimen, four of five recipients developed chimerism and three of these achieved long-term renal allograft survival (>861, >796 and >378 days) without maintenance immunosuppression. Neither chimerism nor long-term allograft survival were achieved in two recipients treated with the belatacept regimen but with a lower, subtherapeutic dose of CyA. This study indicates that CD28/B7 blockade with belatacept can provide a clinically applicable alternative to anti-CD154 mAb for promoting chimerism and renal allograft tolerance. This study shows that belatacept promotes induction of mixed chimerism and renal allograft tolerance in nonhuman primates.

Original languageEnglish
Pages (from-to)2704-2712
Number of pages9
JournalAmerican Journal of Transplantation
Volume14
Issue number12
DOIs
Publication statusPublished - 2014 Dec 1
Externally publishedYes

Fingerprint

Transplantation Tolerance
Chimerism
Primates
Kidney
Allografts
Antilymphocyte Serum
Whole-Body Irradiation
Clinical Protocols
Abatacept
Immunosuppression
Cyclosporine
Maintenance
Therapeutics

Keywords

  • Basic (laboratory) research/science
  • bone marrow/hematopoietic stem cell transplantation
  • kidney transplantation/nephrology
  • tolerance: chimerism
  • tolerance: costimulation blockade
  • tolerance: experimental

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Yamada, Y., Ochiai, T., Boskovic, S., Nadazdin, O., Oura, T., Schoenfeld, D., ... Kawai, T. (2014). Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. American Journal of Transplantation, 14(12), 2704-2712. https://doi.org/10.1111/ajt.12936

Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. / Yamada, Y.; Ochiai, T.; Boskovic, S.; Nadazdin, O.; Oura, T.; Schoenfeld, D.; Cappetta, K.; Smith, R. N.; Colvin, R. B.; Madsen, J. C.; Sachs, D. H.; Benichou, G.; Cosimi, A. B.; Kawai, T.

In: American Journal of Transplantation, Vol. 14, No. 12, 01.12.2014, p. 2704-2712.

Research output: Contribution to journalArticle

Yamada, Y, Ochiai, T, Boskovic, S, Nadazdin, O, Oura, T, Schoenfeld, D, Cappetta, K, Smith, RN, Colvin, RB, Madsen, JC, Sachs, DH, Benichou, G, Cosimi, AB & Kawai, T 2014, 'Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates', American Journal of Transplantation, vol. 14, no. 12, pp. 2704-2712. https://doi.org/10.1111/ajt.12936
Yamada, Y. ; Ochiai, T. ; Boskovic, S. ; Nadazdin, O. ; Oura, T. ; Schoenfeld, D. ; Cappetta, K. ; Smith, R. N. ; Colvin, R. B. ; Madsen, J. C. ; Sachs, D. H. ; Benichou, G. ; Cosimi, A. B. ; Kawai, T. / Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. In: American Journal of Transplantation. 2014 ; Vol. 14, No. 12. pp. 2704-2712.
@article{d5a4da26bfbf4cff9bb2458a96db8f05,
title = "Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates",
abstract = "We have previously reported successful induction of renal allograft tolerance via a mixed chimerism approach in nonhuman primates. In those studies, we found that costimulatory blockade with anti-CD154 mAb was an effective adjunctive therapy for induction of renal allograft tolerance. However, since anti-CD154 mAb is not clinically available, we have evaluated CTLA4Ig as an alternative agent for effecting costimulation blockade in this treatment protocol. Two CTLA4Igs, abatacept and belatacept, were substituted for anti-CD154 mAb in the conditioning regimen (low dose total body irradiation, thymic irradiation, anti-thymocyte globulin and a 1-month posttransplant course of cyclosporine [CyA]). Three recipients treated with the abatacept regimen failed to develop comparable lymphoid chimerism to that achieved with anti-CD154 mAb treatment and these recipients rejected their kidney allografts early. With the belatacept regimen, four of five recipients developed chimerism and three of these achieved long-term renal allograft survival (>861, >796 and >378 days) without maintenance immunosuppression. Neither chimerism nor long-term allograft survival were achieved in two recipients treated with the belatacept regimen but with a lower, subtherapeutic dose of CyA. This study indicates that CD28/B7 blockade with belatacept can provide a clinically applicable alternative to anti-CD154 mAb for promoting chimerism and renal allograft tolerance. This study shows that belatacept promotes induction of mixed chimerism and renal allograft tolerance in nonhuman primates.",
keywords = "Basic (laboratory) research/science, bone marrow/hematopoietic stem cell transplantation, kidney transplantation/nephrology, tolerance: chimerism, tolerance: costimulation blockade, tolerance: experimental",
author = "Y. Yamada and T. Ochiai and S. Boskovic and O. Nadazdin and T. Oura and D. Schoenfeld and K. Cappetta and Smith, {R. N.} and Colvin, {R. B.} and Madsen, {J. C.} and Sachs, {D. H.} and G. Benichou and Cosimi, {A. B.} and T. Kawai",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/ajt.12936",
language = "English",
volume = "14",
pages = "2704--2712",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates

AU - Yamada, Y.

AU - Ochiai, T.

AU - Boskovic, S.

AU - Nadazdin, O.

AU - Oura, T.

AU - Schoenfeld, D.

AU - Cappetta, K.

AU - Smith, R. N.

AU - Colvin, R. B.

AU - Madsen, J. C.

AU - Sachs, D. H.

AU - Benichou, G.

AU - Cosimi, A. B.

AU - Kawai, T.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - We have previously reported successful induction of renal allograft tolerance via a mixed chimerism approach in nonhuman primates. In those studies, we found that costimulatory blockade with anti-CD154 mAb was an effective adjunctive therapy for induction of renal allograft tolerance. However, since anti-CD154 mAb is not clinically available, we have evaluated CTLA4Ig as an alternative agent for effecting costimulation blockade in this treatment protocol. Two CTLA4Igs, abatacept and belatacept, were substituted for anti-CD154 mAb in the conditioning regimen (low dose total body irradiation, thymic irradiation, anti-thymocyte globulin and a 1-month posttransplant course of cyclosporine [CyA]). Three recipients treated with the abatacept regimen failed to develop comparable lymphoid chimerism to that achieved with anti-CD154 mAb treatment and these recipients rejected their kidney allografts early. With the belatacept regimen, four of five recipients developed chimerism and three of these achieved long-term renal allograft survival (>861, >796 and >378 days) without maintenance immunosuppression. Neither chimerism nor long-term allograft survival were achieved in two recipients treated with the belatacept regimen but with a lower, subtherapeutic dose of CyA. This study indicates that CD28/B7 blockade with belatacept can provide a clinically applicable alternative to anti-CD154 mAb for promoting chimerism and renal allograft tolerance. This study shows that belatacept promotes induction of mixed chimerism and renal allograft tolerance in nonhuman primates.

AB - We have previously reported successful induction of renal allograft tolerance via a mixed chimerism approach in nonhuman primates. In those studies, we found that costimulatory blockade with anti-CD154 mAb was an effective adjunctive therapy for induction of renal allograft tolerance. However, since anti-CD154 mAb is not clinically available, we have evaluated CTLA4Ig as an alternative agent for effecting costimulation blockade in this treatment protocol. Two CTLA4Igs, abatacept and belatacept, were substituted for anti-CD154 mAb in the conditioning regimen (low dose total body irradiation, thymic irradiation, anti-thymocyte globulin and a 1-month posttransplant course of cyclosporine [CyA]). Three recipients treated with the abatacept regimen failed to develop comparable lymphoid chimerism to that achieved with anti-CD154 mAb treatment and these recipients rejected their kidney allografts early. With the belatacept regimen, four of five recipients developed chimerism and three of these achieved long-term renal allograft survival (>861, >796 and >378 days) without maintenance immunosuppression. Neither chimerism nor long-term allograft survival were achieved in two recipients treated with the belatacept regimen but with a lower, subtherapeutic dose of CyA. This study indicates that CD28/B7 blockade with belatacept can provide a clinically applicable alternative to anti-CD154 mAb for promoting chimerism and renal allograft tolerance. This study shows that belatacept promotes induction of mixed chimerism and renal allograft tolerance in nonhuman primates.

KW - Basic (laboratory) research/science

KW - bone marrow/hematopoietic stem cell transplantation

KW - kidney transplantation/nephrology

KW - tolerance: chimerism

KW - tolerance: costimulation blockade

KW - tolerance: experimental

UR - http://www.scopus.com/inward/record.url?scp=84910612694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910612694&partnerID=8YFLogxK

U2 - 10.1111/ajt.12936

DO - 10.1111/ajt.12936

M3 - Article

C2 - 25394378

AN - SCOPUS:84910612694

VL - 14

SP - 2704

EP - 2712

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -